| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1191/0961203305LU2194OA |
| P698 | PubMed publication ID | 16218461 |
| P50 | author | Angela Tincani | Q73304219 |
| P2093 | author name string | R Cattaneo | |
| P Riboldi | |||
| C Biasini-Rebaioli | |||
| P2860 | cites work | Surface staining and cytotoxic activity of heat-shock protein 60 antibody in stressed aortic endothelial cells | Q28574641 |
| Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data | Q30978841 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant | Q33381987 | ||
| Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome | Q33495531 | ||
| QT interval prolongation in asymptomatic anti-SSA/Ro-positive infants without congenital heart block | Q33922169 | ||
| Atherosclerosis as an autoimmune disease: an update | Q33956324 | ||
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 | ||
| Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? | Q34601733 | ||
| Autoantibody-mediated atherosclerosis | Q35172086 | ||
| Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report | Q35189299 | ||
| Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus | Q35552185 | ||
| Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome | Q35554870 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. | Q40461525 | ||
| Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome | Q44183283 | ||
| Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus | Q45085322 | ||
| Libman-Sacks endocarditis associated with antiphospholipid syndrome and infection | Q45126480 | ||
| Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations | Q45217508 | ||
| Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. | Q46095021 | ||
| Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome | Q46367698 | ||
| The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort | Q46561334 | ||
| Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta 2-glycoprotein I. | Q47442034 | ||
| P433 | issue | 9 | |
| P921 | main subject | autoantibody | Q785022 |
| P304 | page(s) | 656-659 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Nonorgan specific autoantibodies and heart damage | |
| P478 | volume | 14 |
| Q59130718 | Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS) |
| Q36954468 | B Cell in Autoimmune Diseases |
| Q51835838 | Immune-Mediated Heart Disease. |
| Q30778909 | Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors--data from a multi-ethnic Latin American cohort. |
Search more.